Author Archives: Bruno Quinney

Histology slides
#Cyclana Bio #Endometriosis #NHS

Cyclana Bio gets green light to launch endometriosis trial 

Cyclana Bio has been granted Health Research Authority (HRA) and Research Ethics Committee (REC) approval by the NHS to launch a study into endometriosis.  The biotechnology company will now go ahead with its 500-patient clinical observational study, being called PEMP (Predicting Endometriosis Mechanisms and Populations), to improve understanding of the disease… Read More

#News #Regulatory

FDA headquarters
#AstraZeneca #FDA #Hypertension

FDA approves hypertension treatment in landmark step

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Baxfendy (baxdrostat) in the US for the treatment of hypertension.  Baxfendy has been approved as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled.  AstraZeneca… Read More

#News #Regulatory

Scientist in laboratory
#AI #Clinical trial #iOnctura #Poolbeg Pharma #Regulatory #Synklino #Weatherden

Expert opinion: Navigating the challenges in the clinical trials sector

On International Clinical Trials Day, industry experts speak to DDW about the current state of play within global clinical trials. DDW: How encouraged are you by regulatory reforms – whether it’s a focus on the use of NAMs, or faster regulatory review processes – to help companies conduct more efficient and effective trials? Liam Tremble: A lot… Read More

#Exclusive Content #Regulatory

Kidneys
#European Medicines Agency #Hansa Biopharma #Transplant

Hansa Biopharma and SERB enter €115m licensing agreement 

Hansa Biopharma and SERB have entered a licensing agreement worth €115 million for the development and commercialisation of a treatment for kidney transplant patients.  Idefirix (imlifidase) is a first-in-class treatment that targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by… Read More

#Business & Investment #News

Medical laboratory
#Bispecific Antibodies #Cancer research #Clinical trial

Mestag doses first patient in treatment for solid tumours 

Mestag Therapeutics has dosed the first patient in its Phase I trial evaluating a novel therapeutic strategy to treat solid tumours.  MST-0312 is a bispecific antibody designed to activate lymphotoxin-beta receptor (LTBR) in the tumour microenvironment to induce the formation of tertiary lymphoid structures (TLS) and associated high… Read More

#Cancer Research #News

#AI #Drug discovery #Genomics #Multiomics #Transcriptomics

Advances in genomics for drug discovery 

DDW Editor Reece Armstrong speaks to Michelle Carlson about overall advances in genomics and the integration of emerging technologies to create more drug discovery and development opportunities.  RA: How is long-read sequencing enabling greater clinical research in genomics? MC: Short-read sequencing is effective for identifying single-nucleotide mutations and other small variants that can cause genetic disease. Read More

#Exclusive Content

Genomics
#ALS #Genomics #Longitude Prize #OutSee

OutSee receives Discovery Award from Longitude Prize on ALS 

OutSee has received a Discovery Award from the Longitude Prize on ALS, the genomics and drug discovery company has announced.  The award will grant OutSee access to genomic data from 9,000 amyotrophic lateral sclerosis (ALS) patients, in addition to £100,000 ($134,000) in funding, supporting a research project… Read More

#News

Lung cancer
#Cancer research #Lung cancer #The Francis Crick Institute

Nervous system crucial in lung cancer response, research shows 

Regulating the nervous system could be crucial in the response to lung cancer, new research suggests.   Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system’s response to lung cancer, highlighting a previously unrecognised neuroimmune connection which could be targeted… Read More

#Cancer Research #Editor's Choice #News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

DDW Highlights: 19 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More

#Podcasts

Cell therapy platform
#FDA #Gene therapy #Manufacturing

Cytiva’s transcient cell line receives FDA AMT designation 

The US Food and Drug Administration (FDA) has given an advanced manufacturing technology (AMT) designation to Cytiva’s transient cell line, making it one of the first gene therapy manufacturing technologies to receive the designation.   The ELEVECTA transient cell line for adeno-associated virus (AAV) manufacturing is said to reduce the formation and encapsidation of host cell DNA… Read More

#News #Regulatory

#Clinical trial #GSK #Protas

GSK signs agreement to streamline clinical trials 

GSK has announced an agreement with Protas to streamline clinical trials of vaccines and therapeutics.  The three-year agreement sets out to build on an existing two-year relationship and will broaden the scope of work across numerous projects. This includes Phase II and III trials within GSK’s respiratory,… Read More

#News

#Mediar Therapeutics #Qureight #Sclerosis

Mediar selects Qureight to support systemic sclerosis trial 

Biotechnology company Mediar Therapeutics has enlisted the support of CRO Qureight in the Phase II trial of a treatment for systemic sclerosis.  Qureight’s AI 3D quantitative imaging analytics platform and services will be used to support Mediar’s Phase II EncompaSSc clinical trial. The trial will evaluate MTX-474, a monoclonal antibody therapeutic for people with diffuse cutaneous systemic sclerosis (dcSSc).  Systemic… Read More

#Business & Investment #News

#Mental health #Wellcome Trust

Wellcome and Nature launch $1m mental health science prize 

Wellcome has launched the world’s largest global prize for scientific breakthroughs in mental health.  The Wellcome Prize for Mental Health Science has been launched in a collaboration between charitable foundation Wellcome and scientific journal Nature, offering prizes up to $1 million.  The prize is open for applications from research… Read More

#News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (11 – 15 May) 

News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.  This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.  The top stories:   … Read More

#News

Francis Crick Institute
#DNA #Genomics #The Francis Crick Institute

Crick set to open UK’s first ancient DNA exhibition 

The Francis Crick Institute is set to house the UK’s first ancient DNA exhibition exploring human evolution and disease.  The exhibition, set to open on 16 July 2026, is led by researchers at the Crick’s Ancient Genomics Laboratory.  ‘We Go Way Back’ will uncover findings from… Read More

#News

#Neuroinflammation #Neuroscience #University of Cambridge

Collaboration set to develop neuroinflammation therapeutics 

Neuroscience company AndzonBio2 has announced it will collaborate with the University of Cambridge and Cambridge Enterprise to develop therapeutics for neuroinflammation.  The agreement states the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s world-leading neuroscience capabilities. This will also include the drug discovery platform developed… Read More

#News